Introduction
============

Diabetes mellitus (DM) is one of the most common chronic diseases in nearly all countries, and it has a prevalence of \~7.9% in Turkey.[@b1-opth-10-1797],[@b2-opth-10-1797]

Microvascular complications of DM include retinopathy, nephropathy, and neuropathy. Diabetic retinopathy (DR) is responsible for decreased vision and blindness; studies estimate that 28.5%--40.3% of patients with type 2 diabetes (DM2) had DR.[@b3-opth-10-1797] Retinal abnormalities in DR patients are microaneurysms, intraretinal hemorrhages, lipid exudates, macular edema, capillary occlusion, cotton-wool spots, retinal thickening, and neovascularization.[@b4-opth-10-1797] The duration of hyperglycemia and abnormal blood lipid levels (such as, total cholesterol, low-density lipoprotein \[LDL\], and triglyceride) are defined risk factors for development and progression of DR.[@b4-opth-10-1797]

Evidence suggests that platelets from patients with DM2 have increased reactivity and baseline activation compared to healthy controls.[@b5-opth-10-1797] Mean platelet volume (MPV) and platelet distribution width (PDW) are biomarkers of platelet activation.[@b6-opth-10-1797],[@b7-opth-10-1797] Recently, MPV, PDW, platelet-to-lymphocyte (P/L) ratio, and neutrophil-to-lymphocyte (N/L) ratio have been designated as predictors of microvascular complications of diabetes.[@b8-opth-10-1797] Hematological indices, such as N/L and P/L ratios, and MPV were introduced as novel markers of systemic inflammatory responses.[@b9-opth-10-1797] Moreover, association between MPV and impaired glucose regulation in diabetic patients has also been reported.[@b8-opth-10-1797]

Atherogenic dyslipidemia is characterized by low high-density lipoprotein cholesterol (HDL-c) and/or high triglyceride levels. This dyslipidemia is particularly common in DM2 and has been reported to be associated with both microangiopathy and residual cardiovascular risk in DM2 patients.[@b10-opth-10-1797]--[@b12-opth-10-1797] Recently, it has been shown that LDLs, rich in triglycerides, increase platelet reactivity.[@b13-opth-10-1797] The atherogenic index of plasma (AIP) was calculated as log~10~\[triglyceride/HDL-c\] and correlates inversely with the size of LDL particles. High AIP is shown to reflect hyperinsulinemia and high C-reactive protein levels in the Turkish population.[@b14-opth-10-1797]

The aim of the present study is to evaluate the relationship between the atherogenic index and hematologic inflammatory markers and to evaluate the relationship between these parameters and associated variables in DR patients.

Materials and methods
=====================

This was a retrospective study conducted at the Bursa Yuksek Ihtisas Research and Education Hospital, which is a governmental hospital with 1,050 beds, located in the eastern area of Bursa, Turkey. This study complies with the Declaration of Helsinki. The study was approved by the Bursa Yuksek Ihtisas Ethics Committee. Written informed consent was not required because of the retrospective nature of the study.

A total of 500 outpatients with DM2 monitored by the eye clinic between January and December 2014 and 107 healthy subjects were included in this study. DM was diagnosed according to the American Diabetes Association criteria.[@b14-opth-10-1797]

All demographic and clinical features were collected retrospectively. Inclusion criteria for healthy controls and DM2 patients were age ≥30 years, being treated with oral antidiabetic therapy (sulfonylureas), and undergoing a dilated fundus examination. The selected patients were examined by the same ophthalmologist after pupil dilation, followed by color fundus photography.

This study defines retinopathy as proliferative retinopathy characterized by neovascularization, vitreous hemorrhage, and/or ablation of the retina. The DM2 + DR group consisted of 120 patients (47 males and 73 females) with a mean age of 59.8±9.2 years. The DM2 without DR group consisted of 158 patients (59 males and 99 females) with a mean age of 57.3±12.2 years. The control group consisted of 107 healthy subjects (49 males and 58 females) with a mean age of 60.8±11.6 years.

Patients were excluded if they had macrovascular complications, severe anemia, thrombocytopenia, myelodysplastic syndrome, coagulopathy and recent blood transfusion, history of stroke or central nervous system damage, or chronic renal insufficiency requiring dialysis. A total of 222 cases were excluded.

EDTA-anticoagulated blood samples were analyzed within 1 hour of venipuncture by an automatic blood counter (Mindray BC-5800; Mindray Biomedical Electronics Co., Ltd., Shenzhen, People's Republic of China) and used for whole blood analysis.

Hemoglobin A1c (HbA1c) levels were analyzed with the MQ-2000 PT HbA1c analyzer (Shanghai Hui Zheng Medical Technology Co., Ltd., People's Republic of China).

The levels of creatinine, total cholesterol, triglyceride, and HDL-c were determined using commercially available assay kits (Abbott Diagnostics, Abbott Park, IL, USA) with an Architect C16000 autoanalyzer (Abbott Diagnostics), and LDL-c was estimated using the Friedewald formula. The AIP was calculated as log(triglyceride/HDL-c).[@b14-opth-10-1797] AIP values \<0.11 are associated with low risk of atherosclerosis.[@b15-opth-10-1797]

Glomerular filtration rate (GFR) was estimated using the modification of diet in renal disease abbreviated equation: (GFR =186×\[serum creatinine\]^−1.154^×\[age\]^−0.203^×\[0.742 if female\]).[@b16-opth-10-1797] GFR for the detection of chronic kidney disease is \<60 mL/min/1.73 m^2^ in adults.[@b16-opth-10-1797]

Statistical analysis
--------------------

Statistical analyses were carried out using the Statistical Package for Social Sciences for Windows, Version 21.0 (IBM Corporation, Armonk, NY, USA). Descriptive statistics for each variable were determined. Continuous data were expressed as mean ± standard deviation. After analyzing the normality, statistically significant differences between parameters with Gaussian distributions were tested by a Student's *t*-test; variables with a non-Gaussian distribution were compared using the Mann--Whitney *U*-test. Pearson's or Spearman's correlation coefficients (for data that were not normally distributed) were calculated to evaluate the relationship between variables. A *P*-value \<0.05 was considered as statistically significant.

Results
=======

[Table 1](#t1-opth-10-1797){ref-type="table"} shows the following results: there was no significant difference between the three groups regarding age, sex distribution, and body mass index (*P*\>0.05).

The DM2 duration is longer (15.8±7.3 years vs 8.9±5.6 years) and GFR is lower in DM2 + DR compared to DM2 without DR patients.

MPV ([Figure 1](#f1-opth-10-1797){ref-type="fig"}), PDW, triglycerides, and AIP were higher in DM2 patients compared to control patients, but there was no difference between DM2 + DR and the DM2 without DR patients. Only P/L ratio was different in the DM2 + DR patients compared to DM2 without DR and the control patients ([Table 1](#t1-opth-10-1797){ref-type="table"}).

There is a very weak correlation between the DM2 duration and P/L and the N/L ratios ([Table 2](#t2-opth-10-1797){ref-type="table"}). HbA1c levels correlated very weakly with MPV, PDW, and P/L and weakly with the red cell distribution width (RDW). The atherogenic index correlated very weakly with the P/L ratio, PDW, and RDW. None of the other correlations were statistically significant.

Discussion
==========

The present study showed that inflammation was associated with platelet markers; MPV, PDW, and the P/L ratio were higher in DM2 patients than in controls, but there was no difference between patients with and without retinopathy.

MPV, the machine-calculated measure of thrombocyte volume, acts as a negative or positive acute phase reactant in different inflammatory conditions.[@b7-opth-10-1797],[@b17-opth-10-1797] MPV decreases in acute cases and increases in chronic cases.[@b7-opth-10-1797] The current study is in accordance with previous studies, which showed association of increased MPV with diabetes previously.[@b18-opth-10-1797],[@b19-opth-10-1797] Demirtas et al[@b8-opth-10-1797] also found that MPV, PDW, and P/L ratio were significantly higher in diabetic patients than in the control group, and MPV levels were associated with the DM2 + DR group. Although PDW was not high in DM2 patients, the PDW level correlated weakly with HbA1c in patients in the current study, similar to another recent study.[@b20-opth-10-1797] PDW and MPV may be related to poor glycemic control, possibly due to the osmotic effect resulting from increased glucose levels and some of its metabolites in blood.[@b21-opth-10-1797]

In recent years, the P/L and N/L ratios were introduced as new inflammatory markers in different situations.[@b22-opth-10-1797],[@b23-opth-10-1797] The P/L ratio combines the predictive risk of platelet and lymphocyte counts.

Patients with DM2 + DR have the highest P/L ratio in the current study. An association between the P/L ratio and albuminuria in diabetic nephropathy patients has been determined previously.[@b8-opth-10-1797],[@b24-opth-10-1797] This relationship might be attributed to increased inflammation and impaired antioxidant status in this population. An increase in P/L ratio may reflect the increase in platelet count, and a decrease in lymphocyte count reflects an inflammatory state.[@b25-opth-10-1797] In addition, elevated oxidative damage of lymphocytes in the hyperglycemia state causes lymphocyte apoptosis and may lead to increase in P/L ratio.[@b26-opth-10-1797] In the current study, P/L ratio was weakly associated with the atherogenic index, suggesting that dyslipidemia-induced inflammation contributes to pathological processes that lead to retinopathy.

In the current study, HbA1c, which is a marker of long-term glycemic control, weakly correlated with MPV, PDW, RDW, P/L, and N/L ratios and atherogenic index. This is evidence that hyperglycemia induces nonenzymatic glycation of proteins on the surface of the platelets and erythrocytes, which decreases membrane fluidity and increases its reactivity.[@b27-opth-10-1797] The link between hyperlipidemia and platelet hyperactivation is supported by the previous studies that lipid-lowering agents possess antithrombotic properties.[@b28-opth-10-1797] Adak et al[@b29-opth-10-1797] showed that hyperglycemia-induced oxidative stress leads to structural functional alterations in red blood cells.

Higher RDW levels were found to be associated with low HDL-c levels and unfavorable lipid profile in the normal population.[@b30-opth-10-1797] Membrane fluidity is regulated by the cholesterol content, lipid composition, and protein--lipid interaction in cells, and cell functions are regulated by the cell membranes.[@b31-opth-10-1797] The presence of a higher amount of cholesterol or advanced glycation end products may be responsible for creating a condition of lower fluidity. This also shows that erythrocyte membrane fatty acid components may contribute to alterations in membrane fluidity in patients with DM2, which may play an important role in the development of diabetic microangiopathy.[@b32-opth-10-1797]

Conflicting results have been reported for the relation of platelet count and diabetes. Several studies have reported no relation, while some have reported a positive association between diabetes and platelet count.[@b33-opth-10-1797]--[@b35-opth-10-1797] The current study also found no relation between platelet count and diabetes.

This study has some limitations. It involves a single institution and may not represent the general population; the retrospective design is also a limitation of this study.
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###### 

Demographic and laboratory parameters in patients

  Parameters                                DM2 + DR (n=120)   DM2 without DR (n=158)   Control (n=107)   *P*-value
  ----------------------------------------- ------------------ ------------------------ ----------------- ------------------------------------------------------
  Demographic parameters                                                                                  
   Age (years)                              59.8±9.2           57.3±12.2                60.8±11.6         0.065
   Female/male                              73F/47M            99F/59M                  58F/49M           0.405
   DM duration (years)                      15.8±7.3           8.9±5.6                  --                \<0.001[\*](#tfn1-opth-10-1797){ref-type="table-fn"}
   BMI (kg/m^2^)                            28 (25--30)        27 (25--28)              26 (25--30)       0.11
  Baseline laboratory results                                                                             
   HbA1c                                    9.3±2.0            9.2±2.6                  5.6±0.4           \<0.001[\*](#tfn1-opth-10-1797){ref-type="table-fn"}
   RDW                                      13.7±1.4           14.8±1.2                 14.2±1.2          0.138
   Platelet (10^3^/µL)                      277±90             257±71                   264±83            0.206
   MPV (fL)                                 9.6±1.0            9.7±1.2                  9.3±1.0           0.034[\*](#tfn1-opth-10-1797){ref-type="table-fn"}
   PCT                                      0.20±0.06          0.20±0.04                0.20±0.06         0.084
   PDW                                      16.2±0.5           16.2±0.8                 16.0±0.5          0.08
   N/L ratio                                3.0±4.4            2.4±1.9                  2.4±0.9           0.133
   P/L ratio                                140±87             116±66                   129±55            0.014[\*](#tfn1-opth-10-1797){ref-type="table-fn"}
   T chol (mg/dL)                           205±56             207±54                   206±50            0.908
   TG (mg/dL)                               202±141            187±117                  152±96            0.001[\*](#tfn1-opth-10-1797){ref-type="table-fn"}
   HDL (mg/dL)                              43±13              44±12                    48±12             0.052
   LDL (mg/dL)                              121±40             125±41                   125±39            0.433
   GFR (mL/min)                             66±78              74±24                    78±20             0.012[\*](#tfn1-opth-10-1797){ref-type="table-fn"}
   Atherogenic index log~10~ \[TG/HDL-c\]   0.6±0.3            0.8±1.3                  0.4±0.3           0.01[\*](#tfn1-opth-10-1797){ref-type="table-fn"}

**Note:**

*P*\<0.05.

**Abbreviations:** DM2, type 2 diabetes; DR, diabetic retinopathy; BMI, body mass index; HbA1c, hemoglobin A1c; RDW, red cell distribution width; MPV, mean platelet volume; PCT, plateletcrit; PDW, platelet distribution width; N/L, neutrophil/lymphocyte; P/L, platelet/lymphocyte; T chol, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; GFR, glomerular filtration rate; TG, triglycerides.

###### 

Correlation between variables in all groups (n=385)

                      Plt count   MPV                                                      PDW                                                      P/L                                                      N/L                                                      RDW                                                      Atherogenic index
  ------------------- ----------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- ----------------------------------------------------------
  Atherogenic index                                                                                                                                                                                                                                                                                                            
   *r*                0.040       0.009                                                    **0.159**                                                **−0.167**                                               −0.60                                                    **−0.202**                                               --
   *P*                0.583       0.902                                                    **0.030[\*](#tfn3-opth-10-1797){ref-type="table-fn"}**   **0.040[\*](#tfn3-opth-10-1797){ref-type="table-fn"}**   0.464                                                    **0.022[\*](#tfn3-opth-10-1797){ref-type="table-fn"}**   --
  DM duration                                                                                                                                                                                                                                                                                                                  
   *r*                −0.11       0.061                                                    0.061                                                    **0.164**                                                **0.161**                                                −0.12                                                    −0.123
   *P*                0.859       0.315                                                    0.310                                                    **0.013[\*](#tfn3-opth-10-1797){ref-type="table-fn"}**   **0.011[\*](#tfn3-opth-10-1797){ref-type="table-fn"}**   0.852                                                    0.135
  HbA1c                                                                                                                                                                                                                                                                                                                        
   *r*                0.078       **0.120**                                                **0.137**                                                **−0.157**                                               −0.061                                                   **−0.172**                                               **0.161**
   *P*                0.125       **0.019[\*](#tfn3-opth-10-1797){ref-type="table-fn"}**   **0.007[\*](#tfn3-opth-10-1797){ref-type="table-fn"}**   **0.007[\*](#tfn3-opth-10-1797){ref-type="table-fn"}**   0.295                                                    **0.009[\*](#tfn3-opth-10-1797){ref-type="table-fn"}**   **0.028[\*](#tfn3-opth-10-1797){ref-type="table-fn"}**
  T chol                                                                                                                                                                                                                                                                                                                       
   *r*                0.044       −0.033                                                   0.113                                                    −0.115                                                   −0.052                                                   −0.006                                                   **0.277**
   *P*                0.538       0.647                                                    0.115                                                    0.146                                                    0.295                                                    0.949                                                    \<**0.001[\*](#tfn3-opth-10-1797){ref-type="table-fn"}**

**Notes:**

*P*\<0.05. Values that are statistically significant are indicated in bold.

**Abbreviations:** Plt count, platelet count; MPV, mean platelet volume; PDW, platelet distribution width; N/L, neutrophil/lymphocyte; P/L, platelet/lymphocyte; RDW, red cell distribution width; DM, diabetes mellitus; HbA1c, hemoglobin A1c; T chol, total cholesterol.
